Digest Network Come funziona
Network
/
Società
Me
Non verificato

Merz Therapeutics GmbH

Di cosa scriviamo

FarmaceuticaIndustriaSaluteSanitàScienza

7 comunicati stampa

Guarda tutti i comunicati
26/10/2026
Scienza
Medicina - Varie
Sanità
Farmaceutica
Salute
Eventi
Industria
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 2026
Fonte
Merz Therapeutics GmbH
Emittente
Business Wire
1.00
0
15/10/2026
Scienza
Medicina - Varie
Sanità
Salute
Farmaceutica
Industria
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention
Fonte
Merz Therapeutics GmbH
Emittente
Business Wire
1.00
0
19/06/2026
Farmaceutica
Salute
Industria
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan
Fonte
Merz Therapeutics GmbH
Emittente
Business Wire
1.00
0
28/05/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Merz Therapeutics Presents New Research at World Parkinson Congress 2026, Revealing the Hidden Burden of "OFF" Episodes in Parkinson’s Disease
Fonte
Merz Therapeutics GmbH
Emittente
Business Wire
1.00
0
26/05/2026
Sanità
Salute
Farmaceutica
Mercato del lavoro
Industria
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao
Fonte
Merz Therapeutics GmbH
Emittente
Business Wire
1.00
0
30/01/2026
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Merz Therapeutics Appoints Dan Staner as President, Region Europe
Fonte
Merz Therapeutics GmbH
Emittente
Business Wire
1.00
0
07/10/2025
Salute
Scienza
Farmaceutica
Biotecnologia
Industria
Merz Therapeutics Expands Presence with New Affiliate in Poland
Fonte
Merz Therapeutics GmbH
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0